Mereo BioPharma Group (MREO) Competitors $3.35 +0.06 (+1.82%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MREO vs. AKRO, AMPH, TARS, IRON, CGON, HRMY, GLPG, XNCR, EVO, and ARQTShould you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Akero Therapeutics (AKRO), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), CG Oncology (CGON), Harmony Biosciences (HRMY), Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Mereo BioPharma Group vs. Akero Therapeutics Amphastar Pharmaceuticals Tarsus Pharmaceuticals Disc Medicine CG Oncology Harmony Biosciences Galapagos Xencor Evotec Arcutis Biotherapeutics Akero Therapeutics (NASDAQ:AKRO) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment. Do analysts rate AKRO or MREO? Akero Therapeutics presently has a consensus target price of $46.83, suggesting a potential upside of 59.62%. Mereo BioPharma Group has a consensus target price of $7.40, suggesting a potential upside of 120.90%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Does the MarketBeat Community believe in AKRO or MREO? Akero Therapeutics received 62 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 77.97% of users gave Mereo BioPharma Group an outperform vote while only 63.53% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformAkero TherapeuticsOutperform Votes10863.53% Underperform Votes6236.47% Mereo BioPharma GroupOutperform Votes4677.97% Underperform Votes1322.03% Does the media favor AKRO or MREO? In the previous week, Akero Therapeutics had 7 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 10 mentions for Akero Therapeutics and 3 mentions for Mereo BioPharma Group. Akero Therapeutics' average media sentiment score of 0.75 beat Mereo BioPharma Group's score of 0.43 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mereo BioPharma Group 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders believe in AKRO or MREO? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 7.9% of Akero Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is AKRO or MREO more profitable? Mereo BioPharma Group's return on equity of 0.00% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -32.46% -29.83% Mereo BioPharma Group N/A N/A N/A Which has preferable earnings & valuation, AKRO or MREO? Mereo BioPharma Group has higher revenue and earnings than Akero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$151.76M-$3.75-7.82Mereo BioPharma Group$1M519.74-$29.47MN/AN/A SummaryMereo BioPharma Group beats Akero Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get Mereo BioPharma Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MREO vs. The Competition Export to ExcelMetricMereo BioPharma GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$510.43M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5589.7417.16Price / Sales519.74196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book9.315.094.784.78Net Income-$29.47M$151.83M$120.31M$225.60M7 Day Performance-10.43%-2.14%-1.92%-1.23%1 Month Performance-9.95%-4.56%13.65%0.46%1 Year Performance57.28%8.87%28.34%15.24% Mereo BioPharma Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MREOMereo BioPharma Group2.0938 of 5 stars$3.35+1.8%$7.40+120.9%+63.4%$510.43M$1M0.0040High Trading VolumeAKROAkero Therapeutics4.0824 of 5 stars$29.00+0.4%$46.83+61.5%+31.5%$2.02BN/A-7.7030Insider TradeAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$40.91-3.1%$60.33+47.5%-34.7%$1.97B$644.40M14.081,761TARSTarsus Pharmaceuticals0.3248 of 5 stars$51.39-2.1%$54.20+5.5%+163.2%$1.96B$17.45M-13.7850Gap DownIRONDisc Medicine3.4713 of 5 stars$65.58+1.1%$87.50+33.4%+10.7%$1.95BN/A-16.3078Insider TradeCGONCG Oncology2.1551 of 5 stars$28.43-1.1%$63.88+124.7%N/A$1.92B$684,000.000.0061Insider TradeHRMYHarmony Biosciences4.7827 of 5 stars$32.81+1.3%$47.00+43.2%+6.2%$1.87B$681.88M15.35200Analyst ForecastAnalyst RevisionGLPGGalapagos0.617 of 5 stars$27.00+0.7%$30.75+13.9%-31.8%$1.78B$260.09M0.001,123XNCRXencor4.3207 of 5 stars$25.17+4.7%$36.56+45.2%+18.1%$1.76B$168.34M-7.51280EVOEvotec2.387 of 5 stars$4.68+4.2%$5.93+26.8%-61.6%$1.66B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.855 of 5 stars$13.31+4.9%$15.50+16.5%+476.5%$1.56B$138.71M-7.58150Options Volume Related Companies and Tools Related Companies AKRO Competitors AMPH Competitors TARS Competitors IRON Competitors CGON Competitors HRMY Competitors GLPG Competitors XNCR Competitors EVO Competitors ARQT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MREO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
